Rituximab therapy in autoimmune pulmonary alveolar proteinosis

R. Borie*, M-P. Debray†, C. Laine*, M. Aubier*+ and B. Crestani*++

ABSTRACT: Idiopathic pulmonary alveolar proteinosis is presumed to be an autoimmune disorder that may lead to pulmonary insufficiency. However, steroids do not appear to be effective and the standard of therapy is whole-lung lavage. We report the first case of successful therapy with rituximab, which addresses the pathogenic mechanism of pulmonary alveolar proteinosis.

KEYWORDS: CD20, crazy paving, granulocyte-macrophage colony-stimulating factor, interstitial pneumonia, pulmonary alveolar proteinosis

Pulmonary alveolar proteinosis (PAP) is a rare disorder caused by accumulation of surfactant in pulmonary alveoli, which causes respiratory insufficiency [1–3]. For nearly 90% of cases, the disease is associated with neutralising autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) [2].

The standard of care is symptomatic and consists of whole-lung lavage, which may result in numerous complications [4]. Other available therapies are based on GM-CSF supplementation, which is only effective in almost 50% of cases [5]. Rituximab is a monoclonal antibody directed against the CD20 antigen of B-lymphocytes. Since 1997, rituximab has been approved by the US Food and Drug Administration for the treatment of B-lymphoma. Moreover, rituximab has been demonstrated to be effective in various diseases mediated by autoantibodies, such as rheumatoid arthritis, idiopathic thrombocytopenic purpura and systemic lupus erythematosus [6, 7]. We hypothesised that rituximab could provide clinical benefit for a patient with autoimmune PAP.

CASE REPORT

The diagnosis of autoimmune alveolar proteinosis was made in a 41-yr-old nonsmoker who presented with a dry cough without any remarkable finding on physical examination. The chest radiograph revealed bilateral infiltrates and high-resolution computed tomography (HRCT) showed characteristic diffuse ground-glass opacification superimposed on a reticular pattern. The bronchoalveolar lavage was opaque and contained large and foamy alveolar macrophage and an increased number (43%) of lymphocytes. Bacterial, mycobacterial and fungal cultures were negative. The transbronchial lung biopsy showed near complete filling of the alveolar space and terminal bronchioles by periodic acid-Schiff positive acellular surfactant and confirmed the diagnosis of PAP. A careful review of the clinical history did not detect any exposure to inhaled toxic. HIV testing was negative. The serum anti-GM-CSF immunoglobulin (Ig)G concentration was measured using a competition ELISA adapted from Tanaka et al. [8]. Anti-GM-CSF IgG was detected in the serum by ELISA (concentration: 319 μg·mL⁻¹). A diagnosis of idiopathic PAP was made. At the time of diagnosis, pulmonary function tests were within the normal range (diffusing capacity of the lung for carbon monoxide (DL,CO) 84% of the predicted value), arterial blood gas analysis was normal and no treatment was given.

The clinical situation progressively worsened over the following 3 yrs. The patient reported dyspnoea (evaluated as grade III New York Heart Association). At this time, DL,CO was 59% of the predicted value and arterial oxygen tension was 63 mmHg while breathing room air. Diffuse ground-glass opacification was more extensive on HRCT. Because of concern about complications, the patient refused the therapeutic lavage. After being informed about the potential benefits and risks of the treatment the patient agreed to a trial of rituximab therapy. Rituximab was administered in September 2007 as a 1,000 mg intravenous infusion on day 1 and day 15 without any other therapy. Rituximab was well tolerated and induced, as expected, a sharp decrease in the blood B-lymphocyte count which...
Lung function testing before and every 3 months after rituximab infusion

Evolution of serum anti-granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) immunoglobulin (IgG) concentration, and circulating anti-GM-CSF neutralising activity titre and B-cell blood counts. The level of anti-GM-CSF activity decreased 3 months after rituximab infusion and reduction was confirmed after 12 months, with a parallel decrease of anti-GM-CSF Ig concentration. After the infusion of rituximab, B-cells were not detectable in the blood for 9 months and reappeared at the last visit of follow-up. ● anti-GM-CSF IgG concentration; ▲ anti-GM-CSF neutralising activity titre; ■ B-cell blood count.

lasted for 9 months after infusion. At the last follow-up visit 1 yr later, B-lymphocytes were at 96 mm$^3$. The circulating anti-GM-CSF neutralising activity titre was measured as the serum capacity to neutralise GM-CSF activity on TF1 cells in vitro [2]. Serum anti-GM-CSF IgG concentration and circulating anti-GM-CSF neutralising activity titre decreased 3 months after rituximab infusion (fig. 1). Serum levels of γ-globulins did not change.

Alveolar–arterial gradient at rest was improved 6 months after rituximab infusion but pulmonary function tests and lung CT images did not improve (table 1). However, 9 months after the initial infusion, the patient reported improved dyspnoea (grade I New York Heart Association). CT images and pulmonary function tests showed a clear improvement that was confirmed on the last follow-up visit 12 months after rituximab infusion. CT images showed a decrease of the diffuse ground-glass opacification in both lower lobes, particularly in the left lower lobe (fig. 2). Lung function tests were also improved with an increase in DLCO, alveolar–arterial gradient at rest and desaturation during the 6-min walking test (table 1).

**DISCUSSION**

This observation supports the hypothesis that rituximab could be used as an alternative therapy in patients with autoimmune PAP.

The patient’s improvement was delayed by 9 months following rituximab infusion, although the decrease in the anti-GM-CSF activity was observed 3 months after the infusion. This time difference may be explained by the high titre of circulating anti-GM-CSF neutralising activity observed in this patient and by the delay for recruiting functional macrophages to the alveoli in order to stimulate surfactant clearance. Improvement was clinically, functionally and radiologically evident despite a partial decrease of the circulating anti-GM-CSF neutralising activity and serum anti-GM-CSF IgG concentration by ELISA. Available data suggest that the level of GM-CSF autoantibody detected by ELISA does not correlate with the severity of the pulmonary abnormalities at diagnosis [1]. Furthermore there are conflicting results regarding the correlation of anti-GM-CSF concentration and response to treatment with therapeutic lavage or GM-CSF [5, 9]. To the best of our knowledge, correlation between circulating anti-GM-CSF neutralising activity titre and the severity of the disease, or response to therapy, has never been demonstrated. These results support the theory that a partial but sustained reduction of the anti-GM-CSF IgG concentration and circulating anti-GM-CSF neutralising activity could be sufficient to improve alveolar macrophage function and promote resorption of the lipoproteinaceous material in the lung.

Efficacy of rituximab therapy is another step demonstrating that GM-CSF antibodies are pathogenic and mediate PAP development, as already supported by numerous evidences: 1) anti-GM-CSF IgG are specifically and strongly associated with PAP; 2) mice deficient in GM-CSF developed a lung disease undistinguishable from human PAP; and 3) purified GM-CSF antibodies reproduced in vitro the myeloid cell abnormalities observed in patients with autoimmune PAP [2, 10, 11]. Interestingly, the clearance of the anti-GM-CSF antibodies through plasmapheresis has been shown to improve PAP in a patient who experienced a failure of the previous treatments with therapeutic lung lavage and GM-CSF therapy [12].

**TABLE 1** Lung function testing before and every 3 months after rituximab infusion

<table>
<thead>
<tr>
<th></th>
<th>Before rituximab</th>
<th>3 months</th>
<th>6 months</th>
<th>9 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DLCO %</strong></td>
<td>59</td>
<td>47</td>
<td>48</td>
<td>66</td>
<td>62</td>
</tr>
<tr>
<td><strong>Alveolar–arterial gradient at rest mmHg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6MWT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting saturation %</td>
<td>93</td>
<td>94</td>
<td>94</td>
<td>96</td>
<td>94</td>
</tr>
<tr>
<td>Δsaturation %</td>
<td>2</td>
<td>6</td>
<td>9</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Walk distance m</td>
<td>540</td>
<td>540</td>
<td>515</td>
<td>570</td>
<td>560</td>
</tr>
</tbody>
</table>

DLCO: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-min walking test; Δsaturation: resting saturation–lowest saturation on 6MWT.
Rituximab has previously demonstrated a good safety profile. In particular, rituximab does not increase the risk of serious infections in rheumatoid arthritis [13], which is a concern in PAP patients who are at risk of secondary bacterial and mycobacterial infections [4].

Finally, as ~28% of patients with PAP may spontaneously improve [1], we cannot be certain that the improvement observed in this patient was causally related to the beneficial effect of rituximab therapy, although the time-course of improvement supports this conclusion.

This preliminary observation supports the prospective evaluation of the effect of rituximab therapy in autoimmune pulmonary alveolar proteinosis. In view of the delayed improvement observed in this patient, we suggest that this treatment should be evaluated in patients who require non-urgent therapy.

ACKNOWLEDGEMENTS

B. Crestani designed the protocol; R. Borie, M. Aubier and B. Crestani performed the study; R. Borie and B. Crestani wrote the paper; M-P. Debray reviewed all CT images; and C. Laine performed the anti-GM-CSF dosages.

REFERENCES


